|Awarded On||May 18, 2016|
|Program||Product Development Research|
|Award Mechanism||New Company Product Development Award|
|Principal Investigator/Program Director||Matthew Seavey|
|Cancer Sites||Bladder, Brain and Other Nervous System, Breast, Colorectal, Corpus and Uterus, NOS, Endocrine, Gallbladder, Head and Neck, Kidney and Renal Pelvis, Leukemia, Liver and Intrahepatic Bile Duct, Lung and Bronchus, Lymphoma, Melanoma, Ovary, Pancreas, Prostate, Sarcoma, Stomach, Thyroid|
Cancer immunotherapy, heralded as “Breakthrough of the Year” by the journal Science in 2013, has enormous potential to improve survival, and even cure, patients with many types of cancer. Pelican Therapeutics is developing PTX-25 as an immunotherapy agent for cancer patients. Studies indicate that PTX-25 is a best-in-class product due to specific activation of killer T cells, the strongest predictor of survival benefit in cancer immunotherapy.
Pelican is applying for a CPRIT New Company Product Development Award to transition to a bricks-and-mortar company in the State of Texas. Under the CPRIT award, Pelican will finalize development of PTX-25 and complete a three-part phase I clinical tri...